Two distinct Epithelial to Mesenchymal Transition Programmes Control Invasion and Inflammation in Segregated Tumour Cell Populations

HMGN5, an RNA and Nucleosome binding protein required for chromatin de-condensation and gene activation [RNA-seq]

HMGN5, an RNA and Nucleosome binding protein required for chromatin de-condensation and gene activation [ChIP-seq]

HMGN5, an RNA and Nucleosome binding protein required for chromatin de-condensation and gene activation [CLIP-seq]

Shared patterns of glial transcriptional dysregulation link Huntington's disease and schizophrenia

Shared patterns of glial transcriptional dysregulation link Huntington's disease and schizophrenia

Super-silencer perturbation by EZH2 and REST inhibition leads to large loss of chromatin interactions and reduction in cancer growth [Hi-C]

Super-silencer perturbation by EZH2 and REST inhibition leads to large loss of chromatin interactions and reduction in cancer growth [4C-seq]

Super-silencer perturbation by EZH2 and REST inhibition leads to large loss of chromatin interactions and reduction in cancer growth

Mapping genotypes to chromatin accessibility profiles in single cells [scATAC-seq; Pt01-19;Pt-02 DOGMAseq]

Mapping genotypes to chromatin accessibility profiles in single cells

Spatial transcriptomic profiling of Patient and Patient-corrected bioengineered vascular grafts.

New strategies for the identification of intronic variants related to splicing events in pancreas cancer [RNA-Seq]

Gene expression profiling of ST-HSCs and MPP2 cells conditionally expressing MLL-ENL by RNA-seq

miRNA expression data from exosomes of cardiopulmonary progenitors (CPPs) isolated and cultured in vitro

miR-765 induces angiogenesis by inhibiting dipeptidyl peptidase 4 and increasing fibroblast growth factor 2

Effect of the exosomes from cardiopulmonary progenitors on gene expression of HMEC-1 cells

Mucosal immune response against equine herpesvirus type 1

Effect of the exosomes from cardiopulmonary progenitors on gene expression of H9C2 cells

Low dose ruxolitinib plus cyclosporine to treat murine immune-mediated bone marrow failure